Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

A phase II trial investigating the anti-tumour effects of recombinant human interleukin 6 (rhIL-6) in patients with metastatic renal cell cancer was carried out. RhIL-6 (150 microgram) was administered as a daily subcutaneous injection for 42 consecutive days on an outpatient basis. Forty-nine patie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Stouthard, J. M., Goey, H., de Vries, E. G., de Mulder, P. H., Groenewegen, A., Pronk, L., Stoter, G., Sauerwein, H. P., Bakker, P. J., Veenhof, C. H.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1996
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2074380/
https://ncbi.nlm.nih.gov/pubmed/8611381
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items